Newsbenzinga
Foghorn Therapeutic Announces That The Company And Lilly Will Not Advance The FHD-909 Program Into The Clinical Development Expansion Phase
· Published
Article summary
Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…